 |
|
|
| |
Safety and Tolerability of Elbasvir/Grazoprevir in Patients With
Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials
|
| |
| |
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Sulkowski M1; Dusheiko GM2; Manns MP3; Vierling JM4; Reddy KR5; Kwo P6; Lawitz E7; Brown DD8; Klopfer SO8; Robertson M8; Wahl J8; Barr E8; Haber B8; Charles ED8*
1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2University College London, Institute of Liver and Digestive Health, Royal Free Hospital, London, UK; 3Medical School of Hannover, Hannover, Germany; 4Baylor St. Luke's Medical Center, Houston, TX, USA; 5University of Pennsylvania, Philadelphia, PA, USA; 6Indiana University School of Medicine, Indianapolis, IN, USA; 7The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 8Merck & Co., Inc., Kenilworth, NJ, USA.
*Former employee of Merck & Co., Inc.
|
| |
|
|
|
|
|
